Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response claim is fully supported by the provided XELODA prescribing information, including sections 5.2, 7.2, and Patient Information, and includes the label-recommended monitoring (more frequent INR).
Category Scores
Accurate Statements
Increased risk of bleeding when taking XELODA with vitamin K antagonists (e.g., warfarin), potentially including death, with monitoring of INR more frequently.
Supported by Label sections 5.2 (reported altered coagulation parameters/bleeding including death; clinically significant PT/INR increases; monitor INR more frequently and adjust vitamin K antagonist dose) and 7.2 (XELODA increases exposure of vitamin K antagonists; may alter coagulation parameters/bleeding and could result in death; monitor INR more frequently and refer to vitamin K antagonist prescribing information for dosage adjustment), and Patient Information (“Increased risk of bleeding... such as warfarin” with timing including as soon as a few days after starting and possibly within 1 month after stopping).
Timing/clinical course is consistent with the label (events can occur as soon as a few days after starting and possibly within 1 month after stopping).
Patient Information and Label 7.2 describe events occurring within days and up to 1 month after discontinuation.
Unsupported Statements
Contradictions
Important Omissions
The claim does not explicitly mention altered PT/INR (specific coagulation parameters) or that events can occur within days and up to several months after initiating XELODA (in addition to the earlier onset and up to 1 month after stopping).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements accurately reflect on-label risk and recommended monitoring (more frequent INR) for concomitant vitamin K antagonists.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of some label details about coagulation parameters (PT/INR) and broader event timing (including up to several months after initiating, beyond the provided example timing).
Suggested Improvement
Optionally include that the label reports clinically significant increases in PT and INR and notes event timing can occur within several days and up to several months after initiating XELODA.